Učitavanje...
Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects
AIMS: To compare the pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a biosimilar of adalimumab, with European Union (EU)‐approved Humira and US‐licensed Humira after single subcutaneous doses in healthy subjects. METHODS: In a randomized, double‐blind, parallel‐group study, 180...
Spremljeno u:
| Izdano u: | Br J Clin Pharmacol |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5465341/ https://ncbi.nlm.nih.gov/pubmed/28133772 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13245 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|